Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study

Neurology

Volumn 49, Issue 1, 1997, Pages 162-168

  Lieberman, Abraham ^a   Ranhosky, Alan ^b   Korts, David ^b  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSKINESIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; TREMOR; VERTIGO;

EID: 0030753601     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.1.162     Document Type: Article

References (14)

1. Mierau J, Schneider FJ, Ensinger H, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. Eur J Pharmacol 1995;290:29-36.
2. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-270.
3. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
4. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371.
5. Lieberman A. Dopamine agonists used as monotherapy in de nova PD patients: comparisons with selegiline. Neurology 1992;42(supp 4):37-40.
6. Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson's disease with pergolide. Neurology 1981; 31:675-682.
7. Lieberman AN, Goldstein M, Leibowitz M, et al. Long-term treatment with pergolide: decreased efficacy with time. Neurology 1984;34:223-226.
8. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating response to levodopa/carbidopa. Neurology 1993;43:1981-1984.
9. Olanow CW, Fahn S, Muenter M. A multicenter, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
10. 2 receptors with specific cellular elements in the basal ganglia of the cat: the uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons. Neuroscience 1988;27:851-863.
11. 2 receptor. European J Pharm 1988;225:331-337.
12. 3 receptor: Basic and clinical aspects [review]. Clin Neuropharm 1993;16:293-334
13. 4 receptors. Euro J Pharm 1995;290:29-36.
14. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.